Self-administration of depot medroxyprogesterone acetate subcutaneous injectable contraception (DMPA-SC) is effective, safe and registered in many countries. It shows great potential to improve contraceptive access, continuation, and autonomy, including in low-income and middle-income countries. However, there are challenges to roll out this new efficacious intervention, and major implementation issues have been encountered for scale-up. This study aims to describe the implementation strategies to scale up self-administered DMPA-SC programs, the barriers, and facilitators to these programs, and the outcome of the implementation strategy used.
Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era
